Company: NCEL
Filing Date: 2025-09-10
Form Type: 424B3
Source: 0001213900-25-086600
Chunk: 107

Company: NewcelX Ltd.
Filing Date: 2025-09-10
Form: 424B3
Chunk 107
---
 will increase to a NIS amount (according to the NIS to USD rate as of August28, 2025) equivalent to $93,835, including social benefits; and •Each director on the NLS Board (1) shall receive an annual amount of $25,000, payable quarterly, and a one -timeoption grant equal to 0.2% of the outstanding NLS Common Shares, with the initial vesting over three (3) years, with an exercise price equal to the market price at the Closing; and (2) will enter into indemnification agreements between NLS and members of the board of directors. Additionally, Prof. Michel Revel, MD, Director and Chief Scientific Officer of Kadimastem and the beneficial owner of 1,313,877 Kadimastem Ordinary Shares as of August28, 2025, and Ronen Twito, Executive Chairman and CEO of Kadimastem, and beneficial owner of 367,332 Kadimastem Ordinary shares as of August28, 2025, will benefit directly from the exchange of their Kadimastem Ordinary Shares in exchange for NLS Common Shares resulting from the Merger. Treatment of Kadimastem and Kadimastem’s Equity Awards and Award Plan (Page 145) At the Effective Time each option, restricted share unit, restricted share, warrant or other rights issued and outstanding, whether vested or unvested, to purchase Kadimastem Ordinary Shares, shall be assumed by NLS and converted into an option, warrant, other award, or right, as applicable, to purchase NLS Common Shares in accordance with the terms of the Merger Agreement. For more information please see “ The Merger Agreement — Equity Awards and Warrants” of this proxy statement/prospectus. No Solicitation of Acquisition Proposals (Page 147) NLS also agreed during the period between the signing of the Merger Agreement and the earlier of the Closing or the termination of the Merger Agreement in accordance with its terms, or the Interim Period, not to solicit or enter into any inquiry, proposal or offer, or any indication of interest in making an offer or proposal for an alternative competing transactions, to notify Kadimastem as promptly as practicable in writing of the receipt of any inquiries, proposals or offers, requests for information or requests relating to an alternative competing transaction or any requests for non -publicinformation relating to such transaction, and to keep Kadimastem informed of the status of any such inquiries